Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06362187
Other study ID # STUDY00003238
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date May 2026

Study information

Verified date April 2024
Source Cedars-Sinai Medical Center
Contact Arax Shanlian
Phone (310) 967-1110
Email Arax.Shanlian@cshs.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the research is to test the feasibility and preliminary impact of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) pain. The primary research procedures are questionnaires and biometric Fitbit data. The study will enroll adult patients with CP or RAP.


Description:

Chronic pancreatitis (CP) is a progressive inflammatory disease of the pancreas leading to fibrosis and permanent functional damage.1 Recurrent acute pancreatitis (RAP) refers to the presence of at least two separate documented episodes of pancreatitis with a period of resolution in between. RAP and CP represent a disease continuum and RAP is comprised of individuals at varying risk of progression to CP.2 With annual prevalence of ~110-140 (~350,000-500,000 cases) and 40-50 (~150,000-200,000 cases) per 100,000 population, respectively, both RAP and CP are associated with decreased health-related quality of life (HRQoL), impaired physical function, and frequent hospitalizations.3 Specifically, patients with RAP and CP often suffer from severe pain that impacts physical, social, and emotional wellbeing and leads to lost work productivity. Despite the substantial burden of pain, available therapies are limited in their ability to offer safe and effective analgesia. Although a stepwise approach has been applied to pain management, patients frequently turn to opioids, which can be associated with serious consequences including narcotic bowel syndrome and opioid-induced hyperalgesia.4 Hence, there is a critical gap in managing pain associated with RAP and CP. Therapeutic virtual reality (VR) has emerged as an evidence-based, drug-free, immersive digital technology with established benefits for managing cognitive, affective, and sensory aspects of chronic pain.5,6 Unlike other audiovisual technologies, VR is in its ability to generate meaningful emotional experiences.7 Users of VR wear a head-mounted display that creates a vivid perception of being transported into immersive and emotionally evocative worlds. By stimulating the visual cortex while engaging other senses, VR distracts users from processing nociceptive stimuli while leveraging principles of CBT to enhance attitudes, beliefs, and cognitions about pain in a durable manner that does not require persistent use of VR once cognitive skills are transferred.8 Notably, in November of 2021, the U.S. Food and Drug Administration (FDA) authorized a CBT-based, 8-week, VR treatment course for chronic pain, supported by clinical trials from our team and others revealing evidence of clinical benefits.9 Research indicates that VR offers clinical benefits for a variety of GI conditions including disorders of gut-brain interaction10, perianal abscesses11, sphincter of Oddi dysfunction12. Previously, behavioral interventions such as CBT was emphasized by the International Consensus Guidelines for Chronic Pancreatitis in treating CP related pain when patients experience psychological impact of pain and quality of life has decreased. However, there are no existing study examining whether the benefits of therapeutic VR can also improve psychometric, biometric, and other clinical outcomes in RAP and CP patients. This study aims to determine the feasibility of a home-based, standardized, gut-directed, VR CBT for patients with CP and RAP pain as well as investigate the preliminary impact of a home-based, standardized, gut-directed, VR CBT on clinical and functional outcomes of patients with CP and RAP pain. The study will also aim to isolate the immersive effect of gut-directed VR by comparing it with a non-immersive sham VR (using 2D videos displayed in a VR headset as a sham control) for patients with CP and RAP pain.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date May 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients from the national PROCEED cohort study - Have been diagnosed with CP [as determined by Cambridge 3-4 imaging classification (using CT, MRI, or MRCP) or a histologic diagnosis of CP] or diagnosed with RAP [as determined by two or more attacks of documented pancreatitis (defined by at least two of the three criteria: 1-upper abdominal pain; 2-serum lipase >3 times the upper limit of normal; 3-Typical findings on imaging consistent with pancreatitis), Cambridge <3 imaging classification (using CT, MRI or MRCP) and no prior pancreatic surgery] - Have clinically significant abdominal pain, measured using the standardized NIH PROMIS GI Pain Scale14 and defined as scoring at least 5 points above the nationally normed score (0.5 SD effect size), indicating equal or greater than the minimally clinically important difference (MCID) of abdominal pain - Are 18-75 years of age (age range of PROCEED cohort previously set by NIDDK CPDPC Steering Committee) - Are able to read/write English. The study did not include non-English speakers due to current modules of VR CBT are only available in English. Exclusion Criteria: - Patients who are presenting with a condition that interferes with VR usage (e.g., seizures, facial injury precluding safe placement of headset, visual impairment) - Patients who have cognitive impairment that affects protocol participation - Patients who are recommended for long-term hospitalization - Patients who are estimated to live <3 months from the time of enrollment - Patients who have been diagnosed with a pancreatic tumor - Patients who have been enrolled in an interventional/therapeutic drug trial for chronic or recurrent pancreatitis within the last 6 months

Study Design


Intervention

Device:
Gut Directed VR
The intensive VR experiences are reinforced with daily messages and exercises delivered by a web app available through any smartphone or desktop computer along with text messages. The program follows a protocolized schedule that progressively builds new skills and culminates in transition
Sham Control VR
The same Oculus Quest 2 device as the active treatment group but will only have access to 2D content offered as a form of distraction that does not actively teach cognitive skills, is not interactive, and is not immersive. Specifically, participants in this arm will view standardized, neutral videos of nature scenes from using VR to applying the skills learned in VR to everyday life.

Locations

Country Name City State
United States Marissa Podell Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of home-based VR The primary objective of this study is to determine the feasibility of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pain from chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) based on subject's ability to adhere to and complete the study.
Feasibility will be met if =75% of enrolled patients complete the 12-week study.
End of study (12 Weeks)
Secondary Impact of home-based VR The secondary objective of this study is to investigate the preliminary impact of a home-based, standardized, gut-directed, VR CBT on clinical and functional outcomes of patients with CP and RAP pain.
Health-related quality of life measurements will be collected via questionnaires to assess overall health, quality of life, and pain. An Acceptability Form will be provided during the last visit to gauge the general acceptability of the intervention. This data will be compared with biometric data obtained from a Fitbit device, including step counts, heart rate, and sleep parameters to assess the impact of the treatment.
End of study (12 Weeks)
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting NCT06068426 - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management N/A
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3